Biased multicomponent reactions to develop novel bromodomain inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 9019-9027

  McKeown, Michael R ^a   Shaw, Daniel L ^a   Fu, Harry ^b   Liu, Shuai ^b   Xu, Xiang ^a,c   Marineau, Jason J ^a   Huang, Yibo ^b   Zhang, Xiaofeng ^b   Buckley, Dennis L ^a   Kadam, Asha ^b   Zhang, Zijuan ^b   Blacklow, Stephen C ^a,c   Qi, Jun ^a   Zhang, Wei ^b   Bradner, James E ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN INHIBITOR; N (TERT BUTYL) 2 (4 (3,5 DIMETHYLISOXAZOL 4 YL)PHENYL) IMIDAZO[1,2 ALPHA]PYRAZIN 3 AMINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAF1; UNCLASSIFIED DRUG; ALKANESULFONIC ACID; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; FLUOROCARBON; IMIDAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; LIGAND; MOLECULAR LIBRARY; N-(TERT-BUTYL)-2-(4-(3,5-DIMETHYLISOXAZOL-4-YL)PHENYL)IMIDAZO(1,2-A)PYRAZIN-3-AMINE; NUCLEAR PROTEIN; PERFLUOROOCTANESULFONIC ACID; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; BIOCHEMICAL COMPOSITION; CHEMICAL REACTION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SYNTHESIS; EPIGENETICS; IC50; MEDICAL RESEARCH; MULTICOMPONENT REACTION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION REGULATION; HUMAN; MOLECULAR LIBRARY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ALKANESULFONIC ACIDS; AZEPINES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; FLUOROCARBONS; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; ISOXAZOLES; LIGANDS; MODELS, MOLECULAR; NUCLEAR PROTEINS; PYRAZINES; PYRIDINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 84922814425     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501120z     Document Type: Article

References (48)

1. Sanchez, R.; Zhou, M. M. The role of human bromodomains in chromatin biology and gene transcription Curr. Opin. Drug Discovery Dev. 2009, 12, 659-665
2. Schreiber, S. L.; Bernstein, B. E. Signaling network model of chromatin Cell 2002, 111, 771-778
3. Frank, S. R.; Parisi, T.; Taubert, S.; Fernandez, P.; Fuchs, M.; Chan, H. M.; Livingston, D. M.; Amati, B. MYC recruits the TIP60 histone acetyltransferase complex to chromatin EMBO Rep. 2003, 4, 575-580
4. Vervoorts, J.; Luscher-Firzlaff, J. M.; Rottmann, S.; Lilischkis, R.; Walsemann, G.; Dohmann, K.; Austen, M.; Luscher, B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP EMBO Rep. 2003, 4, 484-490
5. You, J. S.; Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012, 22, 9-20
6. Berg, T. Inhibition of transcription factors with small organic molecules Curr. Opin. Chem. Biol. 2008, 12, 464-471
7. Frye, S. V. The art of the chemical probe Nature Chem. Biol. 2010, 6, 159-161
8. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
9. Prinjha, R. K.; Witherington, J.; Lee, K. Place your BETs: the therapeutic potential of bromodomains Trends Pharmacol. Sci. 2012, 33, 146-153
10. Mujtaba, S.; He, Y.; Zeng, L.; Yan, S.; Plotnikova, O.; Sachchidanand; Sanchez, R.; Zeleznik-Le, N. J.; Ronai, Z.; Zhou, M. M. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation Mol. Cell 2004, 13, 251-263
11. Mujtaba, S.; Zeng, L.; Zhou, M. M. Structure and acetyl-lysine recognition of the bromodomain Oncogene 2007, 26, 5521-5527
12. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231
13. Belkina, A. C.; Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer Nature Rev. Cancer 2012, 12, 465-477
14. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
15. Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Qi, J.; Bradner, J.; Nair, S.; Chen, L. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA Oncogene 2014, 33, 2395-2404
16. Chapuy, B.; McKeown, M. R.; Lin, C. Y.; Monti, S.; Roemer, M. G.; Qi, J.; Rahl, P. B.; Sun, H. H.; Yeda, K. T.; Doench, J. G.; Reichert, E.; Kung, A. L.; Rodig, S. J.; Young, R. A.; Shipp, M. A.; Bradner, J. E. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma Cancer Cell 2013, 24, 777-790
17. Schroder, S.; Cho, S.; Zeng, L.; Zhang, Q.; Kaehlcke, K.; Mak, L.; Lau, J.; Bisgrove, D.; Schnolzer, M.; Verdin, E.; Zhou, M. M.; Ott, M. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes J. Biol. Chem. 2012, 287, 1090-1099
18. Rahman, S.; Sowa, M. E.; Ottinger, M.; Smith, J. A.; Shi, Y.; Harper, J. W.; Howley, P. M. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3 Mol. Cell. Biol. 2011, 31, 2641-2652
19. Dey, A.; Chitsaz, F.; Abbasi, A.; Misteli, T.; Ozato, K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 8758-8763
20. Matzuk, M. M.; McKeown, M. R.; Filippakopoulos, P.; Li, Q.; Ma, L.; Agno, J. E.; Lemieux, M. E.; Picaud, S.; Yu, R. N.; Qi, J.; Knapp, S.; Bradner, J. E. Small-molecule inhibition of BRDT for male contraception Cell 2012, 150, 673-684
21. French, C. A. Pathogenesis of NUT midline carcinoma Annu. Rev. Pathol.: Mech. Dis. 2012, 7, 247-265
22. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
23. Ott, C. J.; Kopp, N.; Bird, L.; Paranal, R. M.; Qi, J.; Bowman, T.; Rodig, S. J.; Kung, A. L.; Bradner, J. E.; Weinstock, D. M. BET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemia Blood 2012, 120, 2843-2852
24. ClinicalTrials.gov; U.S. National Library of Medicine: Bethesda, MD, 2014; www.ClinicalTrials.gov.
25. Liu, X.; Vorontchikhina, M.; Wang, Y. L.; Faiola, F.; Martinez, E. STAGA recruits Mediator to the MYC oncoprotein to stimulate transcription and cell proliferation Mol. Cell. Biol. 2008, 28, 108-121
26. Parisi, F.; Wirapati, P.; Naef, F. Identifying synergistic regulation involving c-Myc and sp1 in human tissues Nucleic Acids Res. 2007, 35, 1098-1107
27. Li, H. H.; Li, A. G.; Sheppard, H. M.; Liu, X. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression Mol. Cell 2004, 13, 867-878
28. Buchmann, A. M.; Skaar, J. R.; DeCaprio, J. A. Activation of a DNA damage checkpoint response in a TAF1-defective cell line Mol. Cell. Biol. 2004, 24, 5332-5339
29. Pijnappel, W. W.; Esch, D.; Baltissen, M. P.; Wu, G.; Mischerikow, N.; Bergsma, A. J.; van der Wal, E.; Han, D. W.; Bruch, H.; Moritz, S.; Lijnzaad, P.; Altelaar, A. F.; Sameith, K.; Zaehres, H.; Heck, A. J.; Holstege, F. C.; Scholer, H. R.; Timmers, H. T. A central role for TFIID in the pluripotent transcription circuitry Nature 2013, 495, 516-519
30. Zhang, W. Fluorous linker-facilitated chemical synthesis Chem. Rev. 2009, 109, 749-795
31. Zhang, W.; Curran, D. P. Synthetic applications of fluorous solid-phase extraction (F-SPE) Tetrahedron 2006, 62, 11837-11865
32. Zhang, W.; Chen, C. H.-T.; Lu, Y.; Nagashima, T. A highly efficient microwave-assisted Suzuki coupling reaction of aryl perfluorooctylsulfonates with boronic acids Org. Lett. 2004, 6, 1473-1476
33. Zhang, W.; Chen, C. H.-T. Fluorous synthesis of biaryl-substituted proline analogs by 1,3-dipolar cycloaddition and Suzuki coupling reactions Tetrahedron Lett. 2005, 46, 1807-1810
34. Lu, Y.; Zhang, W. Microwave-assisted synthesis of a 3-aminoimidazo[1,2- a ]-pyridine/pyrazine library by fluorous multicomponent reactions and subsequent cross-coupling reactions QSAR Comb. Sci. 2004, 23, 827-835
35. Zhou, H.; Zhang, W.; Yan, B. Use of cyclohexylisocyanide and methyl 2-isocyanoacetate as convertible isocyanides for microwave-assisted fluorous synthesis of 1,4-benzodiazepine-2, 5-dione library J. Comb. Chem. 2009, 12, 206-214
36. Zhang, W.; Nagashima, T. Palladium-catalyzed Buchwald-Hartwig type amination of fluorous arylsulfonates J. Fluorine Chem. 2006, 127, 588-591
37. Zhang, Z.-H.; Lü, H.-Y.; Yang, S.-H.; Gao, J.-W. Synthesis of 2,3-dihydroquinazolin-4(1 H)-ones by three-component coupling of isatoic anhydride, amines, and aldehydes catalyzed by magnetic Fe3O4 nanoparticles in water J. Comb. Chem. 2010, 12, 643-646
38. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands J. Med. Chem. 2011, 54, 6761-6770
39. Hewings, D. S.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Picaud, S.; Tumber, A.; Wells, C.; Olcina, M. M.; Freeman, K.; Gill, A.; Ritchie, A. J.; Sheppard, D. W.; Russel, A. J.; Hammond, E. M.; Knapp, S.; Brennan, P. E.; Conway, S. J. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands J. Med. Chem. 2013, 56, 3217-3227
40. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-w.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
41. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C.-w. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides J. Med. Chem. 2012, 55, 587-596
42. Gehling, V. S.; Hewitt, M. C.; Vaswani, R. G.; Leblanc, Y.; Côté, A.; Nasveschuk, C. G.; Taylor, A. M.; Harmange, J.-C.; Audia, J. E.; Pardo, E.; Joshi, S.; Sandy, P.; Mertz, J. A.; Sims, R. J.; Bergeron, L.; Bryant, B. M.; Bellon, S.; Poy, F.; Jayaram, H.; Sankaranarayanan, R.; Yellapantula, S.; Srinivasamurthy, N. B.; Birudukota, S.; Albrecht, B. K. Discovery, design, and optimization of isoxazole azepine BET inhibitors ACS Med. Chem. Lett. 2013, 4, 835-840
43. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W. I.; Robson, S. C.; Chung, C. W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
44. Picaud, S.; Da Costa, D.; Thanasopoulou, A.; Filippakopoulos, P.; Fish, P. V.; Philpott, M.; Fedorov, O.; Brennan, P.; Bunnage, M. E.; Owen, D. R.; Bradner, J. E.; Taniere, P.; OSullivan, B.; Muller, S.; Schwaller, J.; Stankovic, T.; Knapp, S. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains Cancer Res. 2013, 73, 3336-3346
45. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
46. Bienayme, H.; Bouzid, K. A new heterocyclic multicomponent reaction for the combinatorial synthesis of fused 3-aminoimidazoles Angew. Chem., Int. Ed 1998, 37, 2234-2237
47. Anders, L.; Guenther, M. G.; Qi, J.; Fan, Z. P.; Marineau, J. J.; Rahl, P. B.; Lovén, J.; Sigova, A. A.; Smith, W. B.; Lee, T. I.; Bradner, J. E.; Young, R. A. Genome-wide localization of small molecules Nature Biotechnol. 2013, 32, 92-96
48. Toretsky, J. A.; Jenson, J.; Sun, C. C.; Eskenazi, A. E.; Campbell, A.; Hunger, S. P.; Caires, A.; Frantz, C.; Hill, J. L.; Stamberg, J. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients Am. J. Clin. Oncol. 2003, 26, 300-306